Lipid-Lowering Agents - Brazil

Brazil

The projected revenue for the Lipid-Lowering Agents market in Brazil is expected to reach €133.10m in 2024.
It is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of 0.61%, leading to a market volume of €137.20m by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue in this market, with an estimated amount of €4,137.00m in 2024.
In Brazil, the demand for lipid-lowering agents is steadily increasing due to the rising prevalence of cardiovascular diseases and the growing awareness about the importance of cholesterol management.

Key regions: Europe, Brazil, France, Australia, Germany

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for Lipid-Lowering Agents in Brazil has been increasing steadily over the years.

Customer preferences: Brazil has a large population suffering from high cholesterol, which has resulted in a high demand for Lipid-Lowering Agents. Customers in Brazil prefer to use generic drugs due to their lower price compared to branded drugs. Additionally, customers tend to rely on recommendations from their doctors when choosing Lipid-Lowering Agents.

Trends in the market: The Lipid-Lowering Agents market in Brazil has been growing due to the increasing prevalence of cardiovascular diseases. The market is expected to continue to grow due to the growing aging population in Brazil. Furthermore, the Brazilian government has been taking steps to reduce the cost of healthcare services, which has resulted in an increase in the number of people seeking medical care and purchasing Lipid-Lowering Agents.

Local special circumstances: Brazil has a large population with limited access to healthcare services, which has resulted in an increase in the number of people seeking medical care. The Brazilian government has been taking steps to improve access to healthcare services, which has resulted in an increase in the number of people purchasing Lipid-Lowering Agents. Additionally, the Brazilian government has been promoting the use of generic drugs, which has resulted in an increase in the number of people purchasing Lipid-Lowering Agents.

Underlying macroeconomic factors: Brazil has a large population suffering from high cholesterol, which has resulted in an increase in the demand for Lipid-Lowering Agents. The Brazilian government has been taking steps to reduce the cost of healthcare services, which has resulted in an increase in the number of people seeking medical care and purchasing Lipid-Lowering Agents. Furthermore, the growing aging population in Brazil has resulted in an increase in the demand for Lipid-Lowering Agents.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.